Fujifilm's multibillion-dollar expansion spree rolls on with $850M capacity boost in U.S., U.K.

Fujifilm’s contract manufacturing ambitions are swelling—again—to the tune of $850 million. The cash infusion is just the latest in a multibillion-dollar spending spree for the manufacturer.

Angling to grow capacity for biologics such as antibodies, gene therapies and vaccines—including those for COVID-19—the company will plug 90 billion Japanese yen (around $850 million) into its CDMO arm Fujifilm Diosynth Biotechnologies.